Stay updated with breaking news from Source healthcare. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
At the 20th Annual Spine, Orthopedic + Pain Management-Driven ASC Conference, Timothy Davis, MD, and Christopher Teja, MD, discussed the impact of human transcription errors on surgical scheduling. ....
™ (remimazolam injection) US commercial rights to BYFAVO were in-licensed from Cosmo Pharmaceuticals NV (“Cosmo”) in January 2020 and it was approved in July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less which make up around 40m procedures a year in the US, including 25m gastro-intestinal procedures 3 for an estimated >$1.5 billion annual total addressable market 4. References 1. Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative market research responses as follows: National Hospital Discharge Survey, 2006; National Survey of Ambulatory Surgery, 2006 (as revised in 2009); Source Healthcare; NCHS 2005; Life Science Strategy Group, LLC Market Research; Apfel et al.,2004. ....
Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.